Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

被引:313
作者
Lu, Yuanjun [1 ]
Chan, Yau-Tuen [1 ]
Tan, Hor-Yue [1 ]
Li, Sha [1 ]
Wang, Ning [1 ]
Feng, Yibin [1 ]
机构
[1] Univ Hong Kong, Sch Chinese Med, Pofulam, 10 Sassoon Rd, Hong Kong 000000, Peoples R China
关键词
Epigenetic modification; Cancer; Epi-drugs; Combination strategy; Tumour microenvironment; HISTONE DEACETYLASE INHIBITOR; RANDOMIZED PHASE-II; DNA METHYLTRANSFERASE INHIBITOR; MESSENGER-RNA METHYLATION; ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNAS; IN-VITRO; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; MESENCHYMAL TRANSITION;
D O I
10.1186/s12943-020-01197-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
引用
收藏
页数:16
相关论文
共 176 条
[11]   CPG-RICH ISLANDS AND THE FUNCTION OF DNA METHYLATION [J].
BIRD, AP .
NATURE, 1986, 321 (6067) :209-213
[12]   Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study [J].
Bitzer, Michael ;
Horger, Marius ;
Giannini, Edoardo G. ;
Ganten, Tom M. ;
Woerns, Marcus A. ;
Siveke, Jens T. ;
Dollinger, Matthias M. ;
Gerken, Guido ;
Scheulen, Max E. ;
Wege, Henning ;
Zagonel, Vittorina ;
Cillo, Umberto ;
Trevisani, Franco ;
Santoro, Armando ;
Montesarchio, Vincenzo ;
Malek, Nisar P. ;
Holzapfel, Julia ;
Herz, Thomas ;
Ammendola, Astrid S. ;
Pegoraro, Stefano ;
Hauns, Bernhard ;
Mais, Anna ;
Lauer, Ulrich M. ;
Henning, Stefan W. ;
Hentsch, Bernd .
JOURNAL OF HEPATOLOGY, 2016, 65 (02) :280-288
[13]   Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact [J].
Black, Joshua C. ;
Van Rechem, Capucine ;
Whetstine, Johnathan R. .
MOLECULAR CELL, 2012, 48 (04) :491-507
[14]   The Bivalent Genome: Characterization, Structure, and Regulation [J].
Blanco, Enrique ;
Gonzalez-Ramirez, Mar ;
Alcaine-Colet, Anna ;
Aranda, Sergi ;
Di Croce, Luciano .
TRENDS IN GENETICS, 2020, 36 (02) :118-131
[15]   CRA-024781:: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo [J].
Buggy, Joseph J. ;
Cao, Z. Alexander ;
Bass, Kathryn E. ;
Verner, Erik ;
Balasubramanian, Sriram ;
Liu, Liang ;
Schultz, Brian E. ;
Young, Peter R. ;
Dalrymple, Stacie A. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) :1309-1317
[16]   A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors [J].
Candelaria, M. ;
Gallardo-Rincon, D. ;
Arce, C. ;
Cetina, L. ;
Aguilar-Ponce, J. L. ;
Arrieta, O. ;
Gonzalez-Fierro, A. ;
Chavez-Blanco, A. ;
de la Cruz-Hernandez, E. ;
Camargo, M. F. ;
Trejo-Becerril, C. ;
Perez-Cardenas, E. ;
Perez-Plasencia, C. ;
Taja-Chayeb, L. ;
Wegman-Ostrosky, T. ;
Revilla-Vazquez, A. ;
Duenas-Gonzalez, A. .
ANNALS OF ONCOLOGY, 2007, 18 (09) :1529-1538
[17]   Role of histone H3 lysine 27 methylation in polycomb-group silencing [J].
Cao, R ;
Wang, LJ ;
Wang, HB ;
Xia, L ;
Erdjument-Bromage, H ;
Tempst, P ;
Jones, RS ;
Zhang, Y .
SCIENCE, 2002, 298 (5595) :1039-1043
[18]   EZH2 Goes Solo [J].
Cavalli, Giacomo .
SCIENCE, 2012, 338 (6113) :1430-1431
[19]   How Does Multistep Tumorigenesis Really Proceed? [J].
Chaffer, Christine L. ;
Weinberg, Robert A. .
CANCER DISCOVERY, 2015, 5 (01) :22-24
[20]   Aberrations of EZH2 in Cancer [J].
Chase, Andrew ;
Cross, Nicholas C. P. .
CLINICAL CANCER RESEARCH, 2011, 17 (09) :2613-2618